Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.82 |
| ▸ | CA1 | P00915 | 6/20 | 0.82 |
| ▸ | PPARA | Q07869 | 4/20 | 0.71 |
| ▸ | CA12 | O43570 | 3/20 | 0.52 |
| ▸ | CA7 | P43166 | 2/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | RELA | Q04206 | 4/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL62340 | 0.98 | CA2 (0.86) | CA2CA1PPARACA12CA7 | |
| SCHEMBL80252 | 0.95 | CA2 (0.82) | CA2CA1PPARACA12CA7 | |
| SCHEMBL3792229 | 0.95 | CA2 (0.82) | CA2CA1PPARACA12CA7 | |
| SCHEMBL3124345 | 0.95 | CA2 (0.82) | CA2CA1PPARACA12CA7 | |
| SCHEMBL291897 | 0.95 | CA2 (0.82) | CA2CA1PPARACA12CA7 | |
| SCHEMBL3794668 | 0.95 | CA2 (0.82) | CA2CA1PPARACA12CA7 | |
| SCHEMBL4622863 | 0.95 | CA2 (0.82) | CA2CA1PPARACA12CA7 | |
| SCHEMBL1668208 | 0.95 | CA2 (0.82) | CA2CA1PPARACA12CA7 | |
| SCHEMBL1228645 | 0.95 | CA2 (0.82) | CA2CA1PPARACA12CA7 | |
| SCHEMBL3787723 | 0.95 | CA2 (0.82) | CA2CA1PPARACA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7718652-B2 | Substituted benzothiadiazinedioxide derivatives and methods of their use | WYETH LLC (US) | 2010-05-18 | — | — | US | disclosed |
| US-20080161295-A1 | SUBSTITUTED BENZOTHIADIAZINEDIOXIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-07-03 | — | — | US | disclosed |
| WO-2008073958-A2 | SUBSTITUTED BENZOTHIADIAZINEDIOXIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161295-A1 | SUBSTITUTED BENZOTHIADIAZINEDIOXIDE DERIVATIVES AND METHODS OF THEIR USE | SLC6A2, SLC6A4, DBH | CA2 3013/4885CA1 3579/4885PPARA 4004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.